Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Pharma
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study
Ivonescimab showed a 49% PFS benefit against Keytruda in first-line NSCLC. But more hoops lie ahead before the bispecific drug can become king.
Angus Liu
Sep 8, 2024 11:30am
The Fierce 50 of 2024
Sep 9, 2024 5:02am
Social Impact Honorees
Sep 9, 2024 5:01am
Innovation Honorees
Sep 9, 2024 5:01am
Patient Advocacy Honorees
Sep 9, 2024 5:01am
Health Equity Honorees
Sep 9, 2024 5:01am
Marketing News
Madrigal maps out 'Way Forward' for MASH patients with Rezdiffra
Sep 6, 2024 6:30am
Despite trial scare, Travere's IgAN drug wins full FDA approval
Sep 5, 2024 5:40pm
PAHO kicks off educational campaign to destigmatize dementia
Sep 5, 2024 11:53am
AbbVie maintains grip on TV drug ad spending list
Sep 5, 2024 10:22am
See More Marketing News
